NextImmune
NextImmune has identified a novel class of small molecules that suppress unwanted autoimmune responses and transplant rejection responses while maintaining the immune responses needed to defend against infections and cancers.
Total raised
€148k
€147,883
Funding rounds
1
Investors
1
distinct backers
Active since
2022-06
latest 2022-06
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood11
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-06-27 | Other | €148k | Venture Kick | View deal → |
Investors
1Related news
- NextImmune wins CHF 150,000 to develop a new generation of immunosuppressive drugsstartupticker.ch · 2022-06
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy